Research Peptides
A high-purity research peptide studied in cell-growth and muscle research. Available in 1mg, with every batch independently tested and dispatched from the UK.
A high-purity research peptide studied in cell-growth and muscle research. Available in 1mg, with every batch independently tested and dispatched from the UK.
IGF-1 LR3 peptide UK is Crown Peptides' long R3 analogue of insulin-like growth factor 1, available in 1mg strength for laboratory research.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
IGF-1 LR3 is a modified analogue of insulin-like growth factor 1 containing an extended N-terminus and an arginine substitution. These changes reduce binding to several IGF-binding proteins and create a research profile distinct from native IGF-1.
IGF-1 LR3 is used in experimental work on IGF-1 receptor signalling, PI3K-AKT and MAPK pathways, cell growth, differentiation, protein-synthesis signalling and nutrient metabolism. The analogue's reduced interaction with binding proteins (Learn more) makes it useful for studying IGF-receptor biology under conditions that differ from endogenous IGF-1 regulation, alongside related growth-factor research such as [Tesamorelin] and [AOD-9604].
Compound-level reference data. Batch-specific results appear on the Certificate of Analysis.
Work out concentration with the peptide calculatorCrown Peptides IGF-1 LR3 is supplied for controlled laboratory research with batch-specific analytical documentation. High-Performance Liquid Chromatography (HPLC) can assess chromatographic purity, while Mass Spectrometry provides molecular information used to support identity verification.
The batch-specific Certificate of Analysis is the definitive source for the exact purity result, identity data and analytical specification of the material supplied.
Researchers working with IGF-1 LR3 may also be interested in [Tesamorelin], [AOD-9604], [CJC-1295 with DAC], [GHRP-6] and [MOTS-C] — other compounds studied in growth-factor and metabolic signalling research.
IGF-1 LR3 is a modified long-acting research analogue of insulin-like growth factor 1, supplied by Crown Peptides at 1mg strength.
The name refers to the extended analogue containing an arginine substitution at position 3 together with an additional N-terminal sequence.
Research includes IGF-1 receptor signalling, cell growth, differentiation, protein synthesis and nutrient-related signalling.
Its structural modifications alter interactions with IGF-binding proteins, so its experimental behaviour differs from endogenous IGF-1.
Because it is a larger peptide analogue, the batch-specific analytical documentation should be used to confirm exact sequence identity, molecular mass and purity.
Every batch is published openly — identity, purity and batch number, with no account needed.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Each batch undergoes internal analytical verification using chromatographic and spectrometric methods prior to lyophilisation.
• HPLC Analysis
• Mass Spectrometry Confirmation
• Batch Traceability
By purchasing this product you confirm that you are a qualified researcher and that this compound will be used exclusively for laboratory research purposes.
This product is not intended for diagnostic or therapeutic use.
Any human or medical use is strictly prohibited.
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.
Disclaimer: All products are sold strictly for laboratory research purposes only. Not for human or veterinary use, consumption, therapeutic, or diagnostic application. By purchasing, you confirm you are a qualified professional and legally permitted to handle these materials in compliance with all applicable laws and regulations. Misuse, resale for unauthorised purposes, or unlawful application is strictly prohibited. Crown Peptides UK disclaims all liability for improper use, handling, or regulatory non-compliance.